EMA Application withdrawn: Theraloc (nimotuzumab) — Oncoscience AG

View source ↗

Summary

An EMA application for Theraloc (nimotuzumab) by Oncoscience AG has been withdrawn for the glioma indication.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioma

Drugs mentioned

• Theraloc (nimotuzumab)

Snippet

Status: Application withdrawn. Therapeutic area: Glioma. MAH: Oncoscience AG. Decision date: 31/12/2009. Orphan medicine